JW Therapeutics targets Hong Kong listing

By Jonathan Breen
17 Aug 2020

Chinese biotechnology company JW (Cayman) Therapeutics is planning to float on Hong Kong’s stock exchange. It has filed a draft prospectus with the bourse.

JW has appointed Goldman Sachs and UBS as the sponsors for its IPO, according to its application submitted on August 14.

The issuer was co-founded in 2016 by Hong Kong and Shanghai-listed biotech firm WuXi AppTec, and Juno Therapeutics, a subsidiary of US pharmaceutical company Bristol Myers Squibb.


Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial